The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
October 26, 2026
View Complete Issue         Table of Contents 2019 
Iberdomide (Zenbexus) for Multiple Myeloma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Iberdomide (Zenbexus) for Multiple Myeloma (online only)
October 26, 2026 (Issue: 1766)
Iberdomide (Zenbexus – BMS), an oral first-in-class cereblon-modulating protein degrader, has received accelerated approval from the FDA for use in combination with the CD38-directed cytolytic antibody daratumumab (Darzalex Faspro) and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Iberdomide (Zenbexus) for Multiple Myeloma (online only)
Article code: 1766e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.